Conference Menu

Current Event 

Overview 
Short Courses
Part One
Combined Session
Part Two
Faculty
Delegate List
Speaker Interviews
Sponsorship
Hotel and Travel
PDF Download
Poster
Press Pass 
Request Brochure 
Archives 

DVDs 

Corporate Sponsors:

Meso Scale 

Phadia 

Corporate Support Sponsor:

BioAgilytix Labs 

Lead Sponsoring Publications:

Bio-IT World 

Nature 

Science AAAS logo 

The Scientist 

Sponsoring Publications:

Bio Pharm Intl 

Future Medicine 

Insight Pharma Reports 

PharmaVoice 

Web Partners:

Pharm Cast 

Pharmaphorum 

SelectScience.net 


Combined Sessions (Parts One and Two) - Immunogenicity Summit 2011

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!


Download Brochure

Thursday, November 17

12:30 pm Registration for Part Two

1:30 Chairperson’s Remarks

Daniel T. Mytych, Ph.D.Principal Scientist, Clinical Immunology, Amgen, Inc.


CLINICAL IMMUNOGENICITY STRATEGY

1:35 Design and Implementation of Clinical Immunogenicity Program

Meena SubramanyamMeena Subramanyam, Ph.D., Vice President, Translational Sciences & Technology, Biogen Idec, Inc. - Biography

Using case studies this talk will highlight critical quality attributes that can potentially impact the PK/PD properties of the therapeutic, and discuss the value of non-clinical studies and phase I human studies to understand the immunogenicity of the therapeutic. It will also provide recommendations for when and how immunogenicity assessments should be made in the pivotal clinical trials and how to develop an analysis plan to study the impact of anti-drug antibodies on clinical end points.

 GLOBAL REGULATORY CONCERNS

2:05 FDA Guidance on Immunogenicity Testing

Susan KirshnerSusan Kirshner, Ph.D., Associate Chief, Laboratory of Immunology, Therapeutic Proteins, Biotechnology, FDA - Biography

The US FDA published its Draft Guidance for Industry: Assay development for immunogenicity testing of therapeutic proteins in December 2009. The Draft Guidance provides FDA recommendations for the development and validation of assays to test for anti-therapeutic antibodies to protein therapeutics. The Guidance has undergone a period of public comment and the Agency is currently assessing the comments provided by the public with the aim of revising the Draft Guidance. This talk will highlight aspects of the Draft Guidance.

2:35 European Update on Unwanted Immunogenicity of Biologicals and Biosimilars

Robin ThorpeRobin Thorpe, Ph.D., FRCPath, Head, Biotherapeutics Group, National Institute for Biological Standards and Control, UK - Biography

The Biosimilars Working Party of the CHMP has drafted a guideline on unwanted Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins, and a new guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use is being drafted. This presentation will provide an update on unwanted immunogenicity and the status and interpretation of existing EU guidelines. Considerations relevant to the immunogenicity assessment of biosimilars will also be included.

3:05 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:35        Panel Discussion with the Speakers

 ROLE OF T REGULATORY CELLS

4:05 Can Enhancement of T Regulatory Cell Function Decrease Immunogenicity?

Ethan ShevachEthan M. Shevach, M.D., Chief, Cellular Immunology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health - Biography

Studies over the past 15 years have identified a new lineage of T lymphocytes, T Regulatory Cells, that express the transcription factor Foxp3. Foxp3+ Treg are a dedicated population of suppressor T cells and function on multiple different target cell types within the immune system. Foxp3+ Treg cells use a variety of suppressor mechanisms including the secretion of suppressor cytokines. Enhancement of Treg function has been proposed as a novel method for the treatment of autoimmunity and transient activation of Treg may facilitate the induction of tolerance to both allografts and immunogenic proteins.

4:35 End of Plenary Session and Part One



Download Brochure



By Series:
By Region: